Vendor Intelligence Report: Shanghai ERP peptide Biotechnology

Published 3 Jul 2026. 31-page investigative report on who is behind Shanghai ERP peptide Biotechnology: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 95 Finnrick lab tests, ERP records 78 pass / 16 fail, an overall pass rate of 82%. The buyer read is selective: Tirzepatide and Retatrutide sit on the stronger end of the catalog, while HGH and TB-500 are product-specific avoid or independent-test-before-use signals. The middle of the catalog is methodology-sensitive, and routine Finnrick purity/fill testing does not clear endotoxin or sterility risk.

ERP’s non-lab record is unusually fragmented. The public trail begins as a 2025 web-and-forum operation, while open Chinese registry searches did not verify the claimed Shanghai entity. The primary site preserved template artifacts: a 1576 founding year, 0 team members, boilerplate privacy text, and a refund page with unfilled placeholders. Related WordPress and BeikeShop storefronts use differing contacts, Gmail accounts, UK/Hong Kong numbers, and a Louise wholesale subdomain.

The provenance and safety file is the report’s main hook. ERP shop imagery shows Genesis Peptides-branded vials, and a separate Genesis price-list/COA lead raises an unresolved manufacturer-versus-sister-brand question. The highest-severity safety item is outside routine Finnrick testing: an April 2026 community SS-31 case reporting underfill and endotoxin above the assay range, followed by refund refusal, bans, deletion, and bot-flooding allegations. Fortune and Chainalysis add crypto-scale context while reporting no fentanyl linkage.

Inside the full report:

  • Per-product pass/fail rates, trajectories, and methodology-divergence charts for all 8 products
  • Dated event timeline from domain launch through SS-31, Fortune, CBP, and FDA signals
  • Domain and storefront map covering erppeptide.com, erppeptide.shop, and louise.erppeptide.shop
  • Genesis Peptides provenance analysis using vial imagery and COA/price-list leads
  • Payment, fulfillment, dispute-resolution, and copycat-verification findings

Risk assessment

  • Endotoxin and non-routine sterility-control risk — high: SS-31 was reported at 44.10mg against 50mg with endotoxin estimated at 26.790 EU/vial; SLU-PP-332, MOTS-c, and Retatrutide also have reconstitution or cloudiness complaints.
  • Product-specific quality risk: HGH and TB-500 — high: Finnrick records HGH at 43.01% across 5 tests and TB-500 at 39.33% across 4 tests; these are product-specific avoid or independent-test-before-use signals.
  • Methodology-sensitive quality risk: Tesamorelin, BPC-157, and Melanotan II — medium: Tesamorelin 64.66%, BPC-157 68.63%, and Melanotan II 66.15% are not failure-heavy like HGH/TB-500 but should be treated as lot-verification buys.
  • Dispute-resolution and complaint-suppression risk — high: Krysia reports refund refusal, future-order credits, bans, message deletion, and bot flooding after SS-31 concerns were raised.
  • Corporate-identity transparency risk — high: Open registry searches did not verify the claimed Chinese entity, and the primary site retained template placeholders, Gmail contacts, and no verified physical address.
  • Copycat and brand-confusion risk — high: ERP uses multiple domains and contacts, shows Genesis Peptides vial branding, has no captured authorized-channel list, and appears in discussions warning about impersonators.
  • Import/seizure and reship-policy risk — medium: ERP is not named by CBP, but its China-to-distributor model overlaps with CBP-targeted peptide shipment methods and reported seized-order remedies shifted costs back to buyers.
  • Payment-recourse and crypto-exposure risk — medium: Fortune and Chainalysis report about $3.6 million in ERP crypto receipts; crypto and offshore payments reduce buyer recovery options, though Chainalysis reported no fentanyl link.